1. Home
  2. TY vs EYPT Comparison

TY vs EYPT Comparison

Compare TY & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tri Continental Corporation

TY

Tri Continental Corporation

N/A

Current Price

$31.99

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

EYPT

EyePoint Pharmaceuticals Inc.

N/A

Current Price

$15.64

Market Cap

1.5B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
TY
EYPT
Founded
1929
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
TY
EYPT
Price
$31.99
$15.64
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$31.00
AVG Volume (30 Days)
36.9K
1.7M
Earning Date
01-01-0001
05-18-2026
Dividend Yield
3.36%
N/A
EPS Growth
N/A
N/A
EPS
4.78
N/A
Revenue
N/A
$7,539,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$965.51
P/E Ratio
$6.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.54
$3.91
52 Week High
$35.05
$19.11

Technical Indicators

Market Signals
Indicator
TY
EYPT
Relative Strength Index (RSI) 33.00 48.23
Support Level $31.98 $11.88
Resistance Level $33.58 $18.99
Average True Range (ATR) 0.41 1.23
MACD -0.11 -0.04
Stochastic Oscillator 27.94 33.88

Price Performance

Historical Comparison
TY
EYPT

About TY Tri Continental Corporation

Tri-Continental Corp is a United States-based closed-end management investment company. It invests to produce future growth of both capital and income while providing reasonable current income. The fund is divided into two equal segments namely, the equity segment uses quantitative models to select individual stocks whereas the Flexible capital income segment invests across a company's investable capital structure, including stocks, bonds, and convertible securities. The Fund invests in a range of sectors, which include consumer discretionary, consumer staples, energy, financials, healthcare, industrials, information technology, industrials, materials, real estate, telecommunication services, utilities, aerospace and defense, banking, chemicals, and others.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Share on Social Networks: